Text Size

Erlotinib Pharmacokinetics During Doxycycline Treatment for Erlotinib-induced Rash

This study has been withdrawn prior to enrollment.
(Investigator left the institution and decided not to continue with the study.)
Sponsor:
Information provided by:
Northwestern University
ClinicalTrials.gov Identifier:
NCT00803842
First received: December 5, 2008
Last updated: January 19, 2011
Last verified: January 2011
History of Changes

December 5, 2008
January 19, 2011
October 2008
December 2009   (final data collection date for primary outcome measure)
The primary objective of this study is to determine whether administration of doxycycline affects erlotinib PK [ Time Frame: 14 days ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00803842 on ClinicalTrials.gov Archive Site
Secondarily, this study aims to investigate the relationship between erlotinib AUC and rash severity and to evaluate the efficacy of doxycycline in rash management. [ Time Frame: 14 days ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Erlotinib Pharmacokinetics During Doxycycline Treatment for Erlotinib-induced Rash
Evaluation of Erlotinib Pharmacokinetics During Doxycycline Treatment for Erlotinib-induced Rash

A side effect occurring in a majority of patients taking erlotinib (Tarceva®) consists of a skin rash. Sometimes, symptoms associated with the rash necessitate erlotinib dose reduction or discontinuation. Some physicians have successfully treated the erlotinib-induced rash with doxycycline. At the same time, it has been observed that in patients who develop the erlotinib rash, the cancers respond better to erlotinib treatment. This research study is designed to determine how well doxycycline treats the erlotinib rash and whether doxycycline affects the blood levels of erlotinib.
Not Provided
Interventional
Not Provided
Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Non Small Cell Lung Cancer
Drug: doxycycline
Doxycycline (the study drug) will be provided to all subjects as 100 mg tablets. They will be allocated enough doxycycline to last them until their next scheduled visit. The doxycycline tablets should be taken orally (only) at a dosage of 100 mg every 12 hours. Administration of adequate amounts of fluid along with capsule and tablet forms of drugs in the tetracycline class is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration. The doxycycline tablets should not be taken with foods that contain calcium. The absorption of doxycycline is reduced when taking bismuth subsalicylate. Duration of study period if 14 days
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
30
Not Provided
December 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males and females 18 years of age or older.
  • Subjects must have started Tarceva® therapy within three (3) days of trial enrollment.
  • Patients must have signed informed consent prior to registration on study.
  • Currently receiving erlotinib therapy at 150 mg per day for locally advanced or metastatic NSCLC.
  • Patients - both males and females - with reproductive potential (ie, menopausal for less than 1 year and not surgically sterilized) must utilize barrier methods in combination with spermicidal agents for contraception when engaging in sexual intercourse. Women of childbearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to registration.

Exclusion Criteria:

  • Allergy to tetracyclines.
  • Use of concurrent agents for papulopustular rash.
  • Currently receiving anticancer agents other than erlotinib.
  • Inability to interrupt other antibiotic therapy.
  • Current use of topical steroids
  • Current use of systemic immunosuppressants (e.g., methotrexate, cyclosporine, azathioprine, mycophenolate mofetil)
  • Photosensitivity or lupus erythematosus.
  • Active gastroesophageal reflux disease.
  • Women who have a positive pregnancy test or are lactating by history.
  • ECOG performance status ≤3.
  • Self report of current smoking or history of smoking within 60 days of screening, or positive urine cotinine test.

  • Current use of agents that are known to be strong inducers or inhibitors of CYTP3A4:

    • inhibitors: atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfi navir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), voriconazole, grapefruit or grapefruit juice
    • inducers: rifampicin, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital, and St. John's Wort

  • Impaired hepatic function (≤ 30 days before randomization):

    • Alkaline phosphatase > 3x ULN
    • Aspartate aminotransferase (AST) > x ULN
    • Alanine aminotransferase (ALT) > 3 x ULN
    • Total Bilirubin > 1.5 x ULN
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00803842
MEL-120407
Yes
Mario E. Lacouture, MD, Northwestern University
Northwestern University
Not Provided
Principal Investigator: Mario Lacouture, MD Northwestern University
Northwestern University
January 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP